If the UK leaves the EU on Oct. 31 without a deal, the Medicines and Healthcare Products Regulatory Agency will start regulating medical devices and IVDs.
The change will be felt most immediately in Europe, where the Dutch molecular diagnostics company recently secured a CE-IVD mark for its MammaPrint BluePrint kit.
Randox believes its cash commitment will fill its clinical diagnostics pipeline for years to come, and collaborators include specialists in high-resolution imaging and nanotechnology.
Over the next three years, the company and its partners will assess the OneRNA platform to diagnose bladder cancer, select treatment, and measure response and recurrence.
The new European initiative promises to deliver multiple new tests and methods for improving the treatment of breast cancer and rectal cancer.